Transdermal estradiol gel - BHR Pharma

Drug Profile

Transdermal estradiol gel - BHR Pharma

Alternative Names: BHR-200

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator BHR Pharma
  • Class Antineoplastics; Estradiol congeners; Estrenes; Hormonal replacements; Small molecules
  • Mechanism of Action Estrogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 01 Mar 2017 BHR Pharma terminates a phase II trial in Prostate cancer in USA (NCT02349386) due to inability to recruit patients
  • 01 Jul 2015 Phase-II clinical trials in Prostate cancer in USA (Topical) (NCT02349386)
  • 02 Feb 2015 BHR Pharma plans a phase II trial for Prostate cancer (Late-stage disease) in USA (NCT02349386)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top